Skip to content

The CARDIO-TTRansform Scintigraphy Sub-study

CARDIO-TTRansform ION-682884-CS2-Scintigraphy Sub-study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06073587
Enrollment
163
Registered
2023-10-10
Start date
2023-04-04
Completion date
2026-03-25
Last updated
2026-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Keywords

TTR, Amyloidosis, Cardiomyopathy

Brief summary

The purpose of this study is to examine the changes in amyloid myocardial burden in a subset of the population participating in the ION682884-CS2 (NCT04136171) study, up to 150 participants, after treatment with eplontersen or placebo based on scintigraphy scans performed at Week 140 using the Perugini grade score method.

Detailed description

Participants who were randomized in Study ION-682884-CS2 (NCT04136171) and have had a baseline scintigraphy scan will be offered the opportunity to participate in this sub-study which involves optional scintigraphy scans.

Interventions

DIAGNOSTIC_TESTScintigraphy scan

Scans will be performed as specified in the arm description.

Sponsors

Ionis Pharmaceuticals, Inc.
Lead SponsorINDUSTRY
AstraZeneca
CollaboratorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Participants must have been properly randomized into the ION-682884-CS2 study (NCT04136171) and should have had a baseline scintigraphy scan (99mTc-DPD, 99mTc- PYP, and 99mTc-HMDP) within 12 months prior to screening for ION-682884-CS2 with planar and SPECT or SPECT/CT images that can be read by the central reader.

Exclusion criteria

* Must not meet any of the

Design outcomes

Primary

MeasureTime frameDescription
Changes From Baseline in Perugini Grading Score From Scintigraphy Scan Images at Week 140Baseline up to Week 140The Perugini grading scale visually compares tracer uptake in the myocardium and ribs following injection of the bone tracers (99mTc-DPD, 99mTc-Pyrophosphate \[PYP\], or 99mTc-HMDP). The scale includes 4 grade classifications: Grade 0- no cardiac uptake and normal rib uptake, Grade 1- cardiac uptake which is less than rib uptake, Grade 2- cardiac uptake with intensity similar rib uptake, and Grade 3- cardiac uptake greater than rib uptake with mild or absent rib uptake. Visual scores of 2 or greater are classified as ATTR-positive and less than 2 are interpreted as ATTR-negative.

Countries

Spain, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 12, 2026